1. Introduction {#sec1-molecules-22-00291}
===============

Eczema or atopic dermatitis (AD) is a distressing disease associated with pruritus, sleep disturbance and impaired quality of life \[[@B1-molecules-22-00291],[@B2-molecules-22-00291]\]. AD is a common and often persistent skin disease that affects a large percentage of the world's population \[[@B1-molecules-22-00291]\]. Atopy refers to allergic hypersensitivity that is associated with asthma, inhalant allergies (e.g., hay fever), and chronic dermatitis. There is a known hereditary component of the disease, and it is more common in atopic families \[[@B1-molecules-22-00291]\]. Criteria that enable a doctor to diagnose it include the typical appearance and distribution of the rash in a patient with a personal or family history of atopy \[[@B1-molecules-22-00291],[@B3-molecules-22-00291],[@B4-molecules-22-00291]\].

AD is a challenge for modern medicine because it is prevalent, severely affects the quality of life of patients and their families, and causes high socioeconomic costs \[[@B5-molecules-22-00291]\]. While initial studies suggested a Th2 deviation as the primary reason for the disease, numerous studies addressed a genetically predetermined impaired epidermal barrier as the leading cause in a subgroup of patients. Recently, immune changes beyond the initial Th2 concept were defined in AD, with a role for specialized dendritic cells as well as newly identified T helper lymphocyte subsets such as Th17 and Th22 lymphocytes. Furthermore, trigger factors have been expanded beyond classical Th2 allergens such as pollen or house dust mites to microbial products as well as self-antigens.

AD pathophysiology is complex and involves the interplay of various T helper (Th) and T regulatory (Treg) lymphocytes and chemokines \[[@B1-molecules-22-00291],[@B6-molecules-22-00291],[@B7-molecules-22-00291],[@B8-molecules-22-00291],[@B9-molecules-22-00291]\]. Significant advances in our understanding of the pathogenesis of AD have led to improvements in therapy. Assessment of AD and the therapeutic efficacy of various treatments is based on objective clinical scores and measurements \[[@B10-molecules-22-00291]\]. These assessments include measurement of skin parameters (such as skin hydration, transepidermal water loss, erythema, staphylococcal colonization and isolation) and laboratory measurement of AD-related seromarkers \[[@B10-molecules-22-00291],[@B11-molecules-22-00291]\].

Many Th2 chemokines and cytokines are involved in the inflammatory process and have been intensely studied \[[@B8-molecules-22-00291]\]. Correlations with disease severity are demonstrated in C-C motif chemokines (such as CCL17, CCL18, CCL22), interleukins (such as IL-17 and IL-31) and neuropeptides (such as brain-derived neurotrophic factor and substance P) \[[@B6-molecules-22-00291],[@B7-molecules-22-00291],[@B12-molecules-22-00291],[@B13-molecules-22-00291]\]. *Staphylococcus aureus* is a key pathogen in the complex pathophysiology of AD \[[@B14-molecules-22-00291],[@B15-molecules-22-00291],[@B16-molecules-22-00291]\]. *Staphylococcal* enterotoxin B (SEB) has been demonstrated to mediate the disease process \[[@B17-molecules-22-00291]\]. Quantifying the various markers and correlating their levels with clinical scores should lead to a better understanding of AD and improve research and efficacy in its management. We investigated correlations among serum levels of anti-staphylococcal enterotoxin IgE, selected AD-related seromarkers and various clinical parameters of AD.

2. Results {#sec2-molecules-22-00291}
==========

From December 2012 to August 2014, 40 children with AD (23 boys and 17 girls) were recruited ([Table 1](#molecules-22-00291-t001){ref-type="table"}). The median (IQR) age of patients was 13.1 (7.9) years. Their median (IQR) objective Scoring Atopic Dermatitis (SCORAD) and Children Dermatology Life Quality Index (CDLQI) scores, and mean ± SD skin hydration (SH) and transepidermal water loss (TEWL) were 45.0 (11.7), 10.0 (8.0), 32.8 ± 13.5 and 12.1 ± 1.7, respectively. There were 16 (40%) and 24 (60%) patients with moderate and severe AD, respectively \[[@B18-molecules-22-00291]\]. Thirty-six (90%) and seventeen (43%) patients were found to have skin colonized with *S. aureus* or *S. epidermidis*, and sixteen of these patients were colonized with both bacteria. A significantly higher percentage of eosinophils in the differential white cell count (*p* = 0.039), the logarithm of serum total IgE (*p* = 0.008), and the serum concentrations of IFN-γ (*p* = 0.005) and IL-18 (*p* = 0.007) were observed in patients with severe AD compared to those with moderate AD ([Table 2](#molecules-22-00291-t002){ref-type="table"}).

Spearman's correlations (adjusted for age of admission, personal allergic rhinitis and asthma) between blood markers and clinical indices are summarized in [Table 3](#molecules-22-00291-t003){ref-type="table"}. Scatterplots showed weak associations between the serum anti-SEB IgE level with both objective SCORAD and CDLQI ([Figure 1](#molecules-22-00291-f001){ref-type="fig"}), and these associations still existed after regression with adjustment.

Backward stepwise linear regression (controlling for age of admission, personal allergic rhinitis and asthma, and other blood markers) showed the serum anti-SEB IgE level was positively associated with *S. aureus* (B = 0.027, *p* = 0.046) and *S. epidermidis* (B = 0.033, *p* = 0.043) isolations, objective SCORAD (B = 0.445, *p* = 0.007), clinical signs (disease extent (B = 0.554, *p* = 0.006) and intensity (B = 0.099, *p* = 0.012)) and CDLQI (B = 0.421, *p* \< 0.0005). Serum TNF-α (a Th1 cytokine) was associated with objective SCORAD (B = 4.935, *p* = 0.010) ([Table 4](#molecules-22-00291-t004){ref-type="table"}). Associations were also demonstrated with disease extent and IL-18 (an APC cytokine; B = 0.438, *p* = 0.001), TGF-β (a Treg cytokine; B = −0.015, *p* = 0.001) and IL-23 (B = −2.812, *p* = 0.006); pruritus and IL-23 (an APC cytokine, B = 0.387, *p* = 0.007); TEWL and IL-18 (B = 0.040, *p* = 0.010).

3. Discussion {#sec3-molecules-22-00291}
=============

The pathogenesis of atopic dermatitis involves complex interactions between susceptible genes, immunological status, skin barrier defects, infections, and environmental factors \[[@B1-molecules-22-00291],[@B8-molecules-22-00291]\]. Activation of T lymphocytes, dendritic cells, macrophages, keratocytes, mast cells, and eosinophils is characteristic of AD skin inflammatory responses. In particular, it involves the interplay of APC, Th2 and Th1 lymphocytes and chemokines \[[@B1-molecules-22-00291],[@B8-molecules-22-00291]\]. Some of these cells and seromarkers have been demonstrated to correlate closely with clinical signs and scores \[[@B6-molecules-22-00291],[@B7-molecules-22-00291],[@B19-molecules-22-00291]\].

AD is a clinical diagnosis with characteristic itchy skin lesions in a child with xerosis, and a personal or family history of atopy. Clinical investigations are usually not necessary for its diagnosis. The disease is diagnosed according to criteria proposed by Hanifin and Rajka \[[@B20-molecules-22-00291]\], or by the UK working diagnostic criteria \[[@B21-molecules-22-00291]\]. Various domains or parameters of the disease, such as symptomatology, signs, severity and quality of life can be objectively measured \[[@B22-molecules-22-00291],[@B23-molecules-22-00291],[@B24-molecules-22-00291]\]. The disease is readily treated by avoidance of allergens and application of topical emollients, corticostoerids or immunomodulating agents \[[@B1-molecules-22-00291],[@B2-molecules-22-00291]\]. However, there is no immediate cure for the disease. Hence, it is pivotal to manage expectations of the parents and patients.

3.1. Anti-*Staphylococcus* Enterotoxins Immunoglobulin E (anti-SE IgE) {#sec3dot1-molecules-22-00291}
----------------------------------------------------------------------

Bacterial infection, most commonly with *S. aureus*, is the main complication of AD \[[@B1-molecules-22-00291],[@B25-molecules-22-00291]\]. In fact, *Staphylococcus* is pathophysiologically associated with AD \[[@B14-molecules-22-00291],[@B15-molecules-22-00291]\]. The anti-SE IgE responses to *Staphylococcus* have not been well characterized. We demonstrated that the serum anti-SEB IgE level and not anti-SEA IgE was positively associated with *S. aureus* and/or *S. epidermidis* isolations, objective SCORAD, clinical signs and CDLQI. In vivo, staphylococcal enterotoxin B but not viruses or Th1 and Th2 cytokines induced IL-31 in leukocytes \[[@B26-molecules-22-00291]\]. Our findings therefore provide a new link among staphylococcal isolation, subsequent T cell recruitment/activation, and symptom induction in patients with atopic dermatitis.

3.2. Th Cytokines {#sec3dot2-molecules-22-00291}
-----------------

AD involves defective cell-mediated immunity related, in part, to an imbalance in two subsets of CD4- T cells that creates a predominance of T-memory cells in the Th2 pathways and a preferential apoptosis of IFN-γ producing Th1 memory and effector T cells \[[@B27-molecules-22-00291]\]. Th2 cells express a set of cytokines, IL-4, -5, -6, -10 and -13 \[[@B28-molecules-22-00291]\]. These cytokines stimulate the proliferation and differentiation of B lymphocytes and contribute to the hypereosinophilia, high serum IgE level, sustained cutaneous inflammation, histamine release, and pruritus characteristic of the disorder \[[@B29-molecules-22-00291]\]. Compared with extrinsic atopic dermatitis, the intrinsic form is associated with less IL-4 and IL-13 production. Maintenance of chronic inflammation is associated with the predominance of IL-5 and IL-12 expression and eosinophils \[[@B29-molecules-22-00291]\].

T helper lymphocytes can be sub-classified on the basis of their repertoire of cytokines \[[@B6-molecules-22-00291],[@B30-molecules-22-00291]\]. The Th1 family produces IFN-γ, TNF-β, TNF-α, IL-2, Th2 produces IL-4, IL-5, IL-9, IL-13, IL-25, GM-CSF, IL-3, IL-10, and Treg produces TGF-β, IL-10. Th1 cells activate T lymphocytes and monocytes and promote cell-mediated immune responses; Th2 cells produce IL-4, IL-5 and IL-13 and function in the relative absence of IFN-γ to induce allergic immune responses. Among the many Th1 cytokines that have been evaluated, we demonstrated in this study that TNF-α was independently and positively associated with objective SCORAD.

Chemokines are leukocyte chemoattractive proteins of 8--10 kDa that represent the largest family of cytokines encoded in the human genome \[[@B6-molecules-22-00291],[@B31-molecules-22-00291]\]. They are critically important in regulating leukocyte trafficking in vivo and participate in the activation of leukocytes in tissues. The CC and CXC chemokines are involved in mediating allergic inflammation. Although not specifically included in the multiplex kit in the current study, these chemokines have been demonstrated to correlate closely with disease severity \[[@B6-molecules-22-00291]\]. These molecules interact closely in a bi-directional manner with Th1 and Th2 cytokines under the adaptive immune system. For example, CC chemokines regulate the directed locomotion of Th2 cells and eosinophils to sites of allergic inflammation and their secretion is also affected by Th2 cytokines such as IL-4 and IL-13. Chemokines also work closely with the innate immune system, and the activation of which, as mediated through the pattern recognition receptors CD14 and TLRs, results in the increased expression of chemokines and their receptors on a variety of leukocytes.

3.3. Treg Cytokines {#sec3dot3-molecules-22-00291}
-------------------

Regulatory T lymphocytes (Treg) produce the immunosuppressive cytokines transforming growth factor (TGF)-β and IL-10 that are important in actively suppressing or terminating immune responses \[[@B32-molecules-22-00291],[@B33-molecules-22-00291],[@B34-molecules-22-00291]\]. We demonstrated that serum TGF-β of AD children inversely correlated with disease extent. IL-10 appeared to correlate with objective SCORAD, and the extent and intensity of skin lesions, but the associations became insignificant in the linear regression analysis. This phenomenon is complicated and may be explained by *S. aureus* isolation (as colonization/infection). *S. aureus* promotes inflammation in the skin of AD children through concomitant Th2 activation and the silencing of resident Treg cells \[[@B35-molecules-22-00291]\]. Commensals such as *S. epidermidis* may counteract these effects by inducing the release of IL-10 by skin dendritic cells \[[@B15-molecules-22-00291],[@B35-molecules-22-00291]\]. The continuous presence of *Staphylococcus* enterotoxin B (SEB) can trigger an acquired functional impairment of Treg in AD patients and the correlation between the increased frequency of Treg and disease severity supports their important role in AD pathogenesis \[[@B17-molecules-22-00291]\].

3.4. APC Cytokines {#sec3dot4-molecules-22-00291}
------------------

The production of chemokines by antigen-presenting cells (such as CCL18) is enhanced by Th2 cytokines such as IL-4 and IL-13 and suppressed by IFN-γ \[[@B12-molecules-22-00291],[@B36-molecules-22-00291],[@B37-molecules-22-00291],[@B38-molecules-22-00291]\]. Two APC cytokines were investigated in this study. IL-18 is a pleiotrophic APC cytokine that plays an important role in both Th1 and Th2 helper T lymphocyte--mediated immunity \[[@B39-molecules-22-00291]\]. The present study found that the plasma concentration of IL-18 positively correlated with the extent or area of the disease, whereas IL-23, also an APC cytokine, negatively correlated with the extent but positively with pruritus. IL-18, also designated as an IFN-γ--inducing factor, was originally considered a Th1 cytokine by acting through its ability to induce IFN-γ production \[[@B40-molecules-22-00291]\]. Recent studies, however, indicated a more complicated pleiotrophic role for IL-18 than simply the induction of IFN-γ production. IL-18 was reported to induce the production of IgE and Th2 cytokines, and is associated with the pathogenesis and severity of AD in children and adults \[[@B39-molecules-22-00291],[@B41-molecules-22-00291],[@B42-molecules-22-00291],[@B43-molecules-22-00291],[@B44-molecules-22-00291],[@B45-molecules-22-00291]\].

3.5. Quality of Life {#sec3dot5-molecules-22-00291}
--------------------

Quality of life, as evaluated with CDLQI, is an important independent domain in the study of atopic disease \[[@B24-molecules-22-00291]\]. CDLQI has been reported to correlate with several clinical and laboratory parameters \[[@B10-molecules-22-00291],[@B14-molecules-22-00291],[@B24-molecules-22-00291]\]. In this study we confirmed that the atopic factors, namely personal history of asthma, eosinophilia and serum concentration of anti-SEB IgE, were positively and independently associated with CDLQI. These findings provided a research direction towards management of these atopic factors for improving the quality of life of patients with eczema.

In conclusion, we have demonstrated that serum concentrations of anti-SEB IgE as well as Th1, Treg and APC cytokines were associated with various clinical signs and quality of life in AD. Together with previous reports on Th2, other immune cellular players and *Staphylococcus aureus*, we confirmed AD is truly a systemic immunologic disease involving *Staphylococcus*, cellular (e.g., APC, eosinophils, neutrophils, basophils, Th1, Th2, Treg, B cells), humoral, cytokine and chemokine pathophysiology \[[@B6-molecules-22-00291],[@B19-molecules-22-00291],[@B46-molecules-22-00291]\]. As the inflammatory process in AD is complex, it may be impossible to characterize the disease with a single clinical score or seromarker. Quantifying the various markers and correlating their levels with clinical scores may lead to a better understanding of AD and improve research in its management. The availability of relevant laboratory markers is an important additional armamentarium for the ongoing research and treatment of this miserable disease in children. The effects of AD treatment on clinical and immune markers can be studied.

4. Patients and Methods {#sec4-molecules-22-00291}
=======================

AD patients of Chinese ethnicity \<18 years of age were recruited from the pediatric dermatology clinic of a university teaching hospital (Hong Kong, China). AD was diagnosed according to standard criteria \[[@B3-molecules-22-00291],[@B20-molecules-22-00291]\] and its severity and symptomatology including pruritus and sleep loss were evaluated using SCORAD index \[[@B18-molecules-22-00291],[@B21-molecules-22-00291]\]. The SCORAD has been widely employed in AD research. It combines objective signs of extent and intensity and subjective symptoms of pruritus and sleep loss. The objective SCORAD, on the other hand, eliminates the subjective symptoms and provides a severity grading \[[@B18-molecules-22-00291]\]. There is no standard global parameter for assessment of eczema severity but SCORAD is one of the most frequent scores usual in clinical medicine. Quality of life of these AD patients was measured with a validated Chinese version of the Children Dermatology Life Quality Index (CDLQI) \[[@B24-molecules-22-00291],[@B47-molecules-22-00291],[@B48-molecules-22-00291]\]. CDLQI consists of 10 questions and has been extensively translated into many languages and validated. Skin biophysiologic parameters (skin hydration (SH) and transepidermal water loss (TEWL)) were measured by standardized procedure at the right antecubital fossa using the Corneometer CM 825 and the Tewameter TM 210 (Courage Khazaka Electronic GmbH, Cologne, Germany), respectively \[[@B49-molecules-22-00291]\]. Also, skin swabs (Copan Innovation, Brescia, Italy) were collected from the right antecubital fossa and the worst affected site (i.e., lesional skin with oozing or crusting) of the patients by rubbing each area for 5 s \[[@B14-molecules-22-00291],[@B15-molecules-22-00291]\].

Peripheral venous blood was collected from AD patients. Part of the fresh blood was collected into EDTA and used for measuring peripheral eosinophil percentage using the Coulter STKS counter (Beckman-Coulter, Miami, FL, USA). The remaining blood was allowed to clot and centrifuged at 4 °C and 3000× *g* for 10 min and the resulting serum stored immediately at −80 °C until further analysis. Serum total IgE was quantified using micro-particle immunoassay (IMx analyzer, Abbott Laboratories, Chicago, IL, USA). All experiments were conducted according to the manufacturer's specifications.

Anti-SEA IgE and anti-SEB IgE were measured by ImmunoCAP fluorescent enzyme immunoassays (Cat. No. 14-4889-01 (m80) and 14-4890-01 (m81)), which was conducted by loading all the required chemicals in a sequential order to the automatic system Phadia 100 (Phadia, Uppsala, Sweden) according to the manufacturer's instructions. After loading the chemicals, a sequence of reactions would proceed automatically by the system. SEA (m80) (or SEB (m81)) covalently bound to the solid phase would first react with the anti-SEA IgE (or anti-SEB IgE) in the serum sample. After washing away the unbound IgE, β-galactosidase-conjugated mouse monoclonal anti-IgE antibodies were added to form complex with the specific IgE. Following the removal of unbound anti-IgE antibodies, 0.01% 4-methylumbelliferyl α-[d]{.smallcaps}-galactopyranoside was added for fluorescent signal development with the help of β-galactosidase. The enzymatic reaction was then stopped by adding 4% sodium carbonate. The fluorescent signal emitted at the end-point was measured by the system, and the serum level of the specific IgE was calculated automatically based on the standard curve. A serum specific IgE level of 0.35 kU/L or greater was considered positive to the specific allergen sensitization.

Concentrations of other seromarkers IFN-γ, TNF-α, IL-9, IL-10, IL-12, IL-18 and IL-23 were measured using the ProcartaPlex magnetic bead-based multiplex assay (Cat. No. EPX180-12165-901; eBioscience, Vienna, Austria); while TGF-β concentration was determined with the ProcartaPlex magnetic bead-based simplex assay (Cat. No. EPX010-10249-901). 50 μL of magnetic beads coated with cytokine-specific capture antibodies was added to each well of a ProcartaPlex 96-well flat bottom plate, followed by 2 min incubation to coat the plate with the magnetic beads, and aspiration by washing buffer to remove unbound beads. Then, 25 μL of serum samples or standards and 25 μL of universal assay buffer were added to each well. The plate was incubated with shaking for 2 h, which allowed the cytokines to bind to their respective immobilized specific magnetic beads. After aspiration, 25 μL of biotinylated cytokine-specific detection antibody was added, followed by incubation with shaking for 30 min to allow binding to the bead-cytokine complex. Following aspiration was the addition of 50 μL of Streptavidin-Phycoerythrin (SA-PE) and incubation with shaking for 30 min to allow the binding between biotin and SA. All incubations were carried out at room temperature in the dark. Finally, the plate was aspirated again, and 120 μL of reading buffer was added to re-suspend the beads from the bottom of each well. The plate containing the bead complex suspensions was read using Bio-Plex 200 (BioRad; Hercules, CA, USA). The concentrations of different cytokines in each serum sample could then be calculated automatically based on the respective standard curves. The simplex assay was conducted in a similar way as the multiplex assay, except that serum samples needed to be pre-treated with 1 N HCl and 1.2 N NaOH/0.5 M HEPES to convert the inactive form of TGF-β to the active form of TGF-β1 because only the bioactive form of TGF-β was immunoreactive and detectable.

Data were expressed as proportion, or mean and standard deviation (SD) (or median and interquartile range (IQR) if data were not normally distributed). Pearson's chi-squared test (or Fisher's exact test if more than 20% of cells with expected frequencies less than 5) and independent samples *t*-test (or Mann-Whitney U test if data were not normally distributed) were used to analyze categorical and numerical variables between groups, respectively. The correlations between different blood markers and clinical indices were analyzed by Spearman's correlation coefficients. Backward stepwise linear regression was conducted using IBM SPSS 20.0 to investigate the independent associations. All comparisons were made two-tailed, and *p*-values less than 0.05 were considered to be statistically significant. Informed written consent was obtained from parents, and Clinical Research Ethics Committee of our University approved this study.

The project is partly funded by a CUHK Direct Grant for Research.
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###### 

Demographics and clinical parameters of patients with moderate and severe AD.

                                        Total (*n* = 40)   Moderate AD (*n* = 16)   Severe AD (*n* = 24)   *p*           
  ------------------------------------- ------------------ ------------------------ ---------------------- ------------- ------------
  Demographics                                                                                                           
  Age, years                            13.1 (7.9)         12.8 (7.2)               13.7 (6.5)             0.345 \*      
  Sex--Male, *n* (%)                    23 (57.5)          10 (62.5)                13 (54.2)              0.601         
  Personal allergic rhinitis, *n* (%)   28 (70.0)          10 (62.5)                18 (75.0)              0.490 \*\*    
  Personal asthma, *n* (%)              19 (47.5)          6 (37.5)                 13 (54.2)              0.301         
  Clinical parameters                                                                                                    
  Objective SCORAD                      45.0 (11.7)        38.2 (8.7)               48.6 (6.5)             \<0.0005 \*   
  *Extent*, %                           54.7 ± 14.8        43.9 ± 13.0              61.8 ± 11.2            \<0.0005      
  *Intensity*                           9.5 (3.0)          8.0 (2.0)                10.5 (2.0)             \<0.0005 \*   
  Pruritus                              6.7 ± 1.9          6.6 ± 1.9                6.8 ± 1.9              0.786         
  Sleep loss                            5.9 ± 2.8          5.9 ± 2.6                5.9 ± 3.0              0.946         
  CDLQI                                 10.0 (8.0)         10.0 (8.0)               10.5 (9.0)             0.594 \*      
  SH                                    32.8 ± 13.5        37.4 ± 13.2              29.7 ± 13.0            0.078         
  TEWL, g/m^2^/h                        12.1 ± 1.7         11.7 ± 1.3               12.4 ± 1.8             0.181         
  *S. aureus*, *n* (%) ^\#^             No                 4 (10.0)                 2 (12.5)               2 (8.3)       0.184 \*\*
  Scanty                                18 (45.0)          10 (62.5)                8 (33.3)                             
  Moderate                              15 (37.5)          3 (18.8)                 12 (50.0)                            
  Heavy                                 3 (7.5)            1 (6.2)                  2 (8.3)                              
  *S. epidermidis*, *n* (%) ^\#^        No                 23 (57.5)                8 (50.0)               15 (62.5)     0.150 \*\*
  Scanty                                11 (27.5)          7 (43.8)                 4 (16.7)                             
  Moderate                              6 (15.0)           1 (6.2)                  5 (20.8)                             

AD, atopic dermatitis; CDLQI, Children's Dermatology Life Quality Index; SCORAD, SCORing Atopic Dermatitis; SH, skin hydration; TEWL, transepidermal water loss. Numerical data expressed in either mean ± standard deviation or median (interquartile range) depending on the distribution normality. \* Mann-Whitney *U* test; \*\* Fisher's exact test; ^\#^ Bacterial isolation in the worst affected skin area.
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###### 

Concentrations of seromarkers in patients with moderate and severe AD.

  Blood/Serum Markers             Total (*n* = 40)         Moderate AD (*n* = 16)   Severe AD (*n* = 24)     *p*
  ------------------------------- ------------------------ ------------------------ ------------------------ ----------
  Eosinophil % in WBC             10.0 (7.0)               9.0 (6.0)                10.5 (6.0)               0.039 \*
  log (Total IgE count in kU/L)   3.79 ± 0.51              3.53 ± 0.57              3.96 ± 0.39              0.008
  Anti-SEA IgE, kU/L              0.81 (2.68)              0.37 (2.64)              1.17 (2.66)              0.279 \*
  Anti-SEB IgE, kU/L              0.90 (3.15)              0.83 (1.96)              1.10 (2.87)              0.202 \*
  IFN-γ, pg/mL                    5.83 (6.24)              4.76 (2.86)              9.04 (6.79)              0.005 \*
  TGF-β, pg/mL                    607 (530)                804 (526)                558 (489)                0.192 \*
  TNF-α, pg/mL                    1.90 (1.07)              1.74 (1.21)              2.06 (0.91)              0.165 \*
  IL-9, pg/mL                     0.71 (1.16) (*n* = 34)   0.41 (0.89) (*n* = 12)   0.71 (1.11) (*n* = 22)   0.276 \*
  IL-10, pg/mL                    0.51 (0.58) (*n* = 29)   0.41 (0.53) (*n* = 9)    0.63 (0.45) (*n* = 20)   0.077 \*
  IL-12, pg/mL                    0.44 (0.20)              0.37 (0.10)              0.44 (0.2)               0.079 \*
  IL-18, pg/mL                    18.15 (15.95)            13.68 (9.50)             22.96 (20.81)            0.007 \*
  IL-23, pg/mL                    1.08 (0.46)              1.08 (0.46)              1.08 (0.46)              0.946 \*

AD, atopic dermatitis; IFN, interferon; IL, interleukin; SE, staphylococcus enterotoxin; TGF, transforming growth factor; TNF, tumor necrosis factor; WBC, white blood cell. Data expressed in either mean ± standard deviation or median (interquartile range) depending on the distribution normality. \* Mann-Whitney *U* test.
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###### 

Adjusted Spearman's correlations between seromarkers and clinical indices (*n* = 40; adjusted for age of admission, personal allergic rhinitis and personal asthma).

                                    *S. aureus* Density \*   *S.* *epidermidis* Density \*   Objective SCORAD   Extent, %    Intensity    Pruritus     Sleep Loss   CDLQI       SH          TEWL, g/m^2^/h   
  --------------------------------- ------------------------ ------------------------------- ------------------ ------------ ------------ ------------ ------------ ----------- ----------- ---------------- --------
  *S. aureus* isolation \*          rho                                                      0.093              **0.436**    0.237        **0.459**    **0.503**    0.208       0.007       −0.198           0.280
  *p*                                                        0.583                           **0.007**          0.158        **0.004**    **0.002**    0.217        0.969       0.240       0.094            
  *S.* *epidermidis* isolation \*   rho                                                                         0.045        0.103        0.013        **0.342**    0.209       0.134       0.044            −0.012
  *p*                                                                                        0.791              0.545        0.938        **0.038**    0.215        0.428       0.797       0.942            
  Eosinophil % in WBC               rho                      **0.478**                       0.015              **0.476**    **0.362**    **0.448**    0.295        0.275       **0.425**   **−0.370**       −0.024
  *p*                               **0.003**                0.928                           **0.003**          **0.028**    **0.005**    0.077        0.100        **0.009**   **0.024**   0.889            
  log(Total IgE count in kU/L)      rho                      **0.436**                       0.053              **0.552**    **0.423**    **0.518**    **0.415**    0.179       **0.405**   **−0.350**       0.122
  *p*                               **0.007**                0.756                           **0.000**          **0.009**    **0.001**    **0.011**    0.288        **0.013**   **0.034**   0.473            
  Anti-SEA IgE, kU/L                rho                      0.051                           −0.083             0.214        −0.009       0.209        0.173        −0.097      **0.399**   −0.032           −0.107
  *p*                               0.764                    0.626                           0.204              0.957        0.214        0.306        0.566        **0.014**   0.850       0.528            
  Anti-SEB IgE, kU/L                rho                      0.167                           0.031              **0.361**    0.290        **0.342**    0.206        0.031       **0.360**   **−0.416**       0.105
  *p*                               0.324                    0.854                           **0.028**          0.081        **0.038**    0.221        0.856        **0.029**   **0.010**   0.538            
  IFN-γ, pg/mL                      rho                      **0.339**                       −0.120             **0.531**    **0.530**    **0.516**    0.324        0.204       −0.047      −0.227           0.193
  *p*                               **0.040**                0.478                           **0.001**          **0.001**    **0.001**    0.050        0.225        0.780       0.177       0.252            
  TGF-β, pg/mL                      rho                      −0.110                          0.108              −0.191       −0.259       −0.122       −0.007       0.098       0.157       0.084            −0.091
  *p*                               0.517                    0.523                           0.258              0.121        0.473        0.968        0.564        0.353       0.619       0.592            
  TNF-α, pg/mL                      rho                      0.231                           −0.038             **0.422**    **0.593**    **0.371**    0.258        0.264       0.070       −0.132           0.066
  *p*                               0.168                    0.825                           **0.009**          **0.000**    **0.024**    0.123        0.114        0.680       0.437       0.697            
  IL-9, pg/mL (*n* = 34)            rho                      −0.065                          −0.201             0.202        **0.562**    0.115        0.123        0.282       −0.138      −0.184           0.072
  *p*                               0.730                    0.279                           0.275              **0.001**    0.536        0.509        0.124        0.460       0.322       0.702            
  IL-10, pg/mL (*n* = 29)           rho                      0.228                           −0.084             **0.554**    **0.571**    **0.468**    −0.043       0.218       0.007       −0.002           −0.100
  *p*                               0.264                    0.684                           **0.003**          **0.002**    **0.016**    0.836        0.284        0.974       0.994       0.627            
  IL-12, pg/mL                      rho                      0.254                           −0.071             **0.390**    **0.570**    **0.331**    0.234        0.060       −0.204      −0.196           0.215
  *p*                               0.129                    0.676                           **0.017**          **0.000**    **0.045**    0.164        0.723        0.226       0.244       0.201            
  IL-18, pg/mL                      rho                      **0.426**                       0.042              **0.587**    **0.547**    **0.562**    **0.380**    0.261       0.022       −0.121           0.268
  *p*                               **0.009**                0.804                           **0.000**          **0.000**    **0.000**    **0.020**    0.119        0.899       0.474       0.109            
  IL-23, pg/mL                      rho                      0.309                           0.016              0.202        0.301        0.166        **0.389**    **0.338**   −0.080      −0.083           0.042
  *p*                               0.063                    0.925                           0.231              0.070        0.327        **0.017**    **0.041**    0.637       0.623       0.807            
  SH                                rho                      −0.198                          0.044              **−0.352**   **−0.356**   **−0.337**   −0.200       −0.267      −0.320                       0.163
  *p*                               0.240                    0.797                           **0.033**          **0.031**    **0.041**    0.234        0.111        0.054                   0.335            
  TEWL, g/m^2^/h                    rho                      0.280                           −0.012             0.214        0.158        0.215        0.277        0.205       −0.225                       
  *p*                               0.094                    0.942                           0.203              0.349        0.200        0.097        0.223        0.181                                    

Significant correlations are highlighted in bold. \* Bacterial isolation in the worst affected skin area: no growth, scanty, moderate and heavy growth.
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###### 

Results of backward stepwise linear regression (controlling for age of admission, personal allergic rhinitis and asthma, and other blood markers that had rho ≤−0.2 or ≥0.2 with the clinical index).

  ------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  ***S. aureus*** **Isolation**        \% of eosinophils in blood white cell counts (B = 0.083, *p* = 0.001), serum concentration of anti-SEB IgE (B = 0.027, *p* = 0.046) and TEWL (B = 0.224, *p* = 0.004) were positively and independently associated with *S. aureus* isolation.
  ***S. epidermidis*** **Isolation**   Serum concentration of anti-SEB IgE (B = 0.033, *p* = 0.043) was positively associated with *S. epidermidis* isolation.
  **Objective SCORAD**                 \% of eosinophils in blood white cell counts (B = 0.843, *p* = 0.003), serum concentrations of anti-SEB IgE (B = 0.445, *p* = 0.007) and TNF-α (B = 4.935, *p* = 0.010) were positively and independently associated with objective SCORAD.
  **Extent**                           Serum concentrations of anti-SEB IgE (B = 0.554, *p* = 0.006) and IL-18 (B = 0.438, *p* = 0.001) were positively and independently associated with extent, while serum concentrations of TGF-β (B = −0.015, *p* = 0.001) and IL-23 (B = −2.812, *p* = 0.006), and SH (B = −0.605, *p* = 0.001) were negatively and independently associated with extent.
  **Intensity**                        Presence of personal asthma (B = 1.265, *p* = 0.044), % of eosinophils in blood white cell counts (B = 0.197, *p* = 0.004), serum concentration of anti-SEB IgE (B = 0.099, *p* = 0.012) and TEWL (B = 0.421, *p* = 0.040) were positively and independently associated with intensity.
  **Pruritus**                         *S. aureus* density (B = 0.815, *p* = 0.004) and *S. epidermidis* density (B = 0.709, *p* = 0.010), and serum concentration of IL-23 (B = 0.387, *p* = 0.007) were positively and independently associated with pruritus, while age of admission (B = −0.216, *p* \< 0.0005) was negatively associated with pruritus.
  **Sleep Loss**                       *S. epidermidis* density (B = 1.478, *p* = 0.038) was positively associated with sleep loss, while age of admission (B = −0.392, *p* = 0.002) and presence of personal asthma (B = −2.386, *p* = 0.027) were negatively and independently associated with sleep loss.None of the studied blood markers were independently associated with sleep loss.
  **CDLQI**                            Presence of personal asthma (B = 3.441, *p* = 0.041), % of eosinophils in blood white cell counts (B = 0.482, *p* = 0.004) and serum concentration of anti-SEB IgE (B = 0.421, *p* \< 0.0005) were positively and independently associated with CDLQI; while age of admission (B = −0.361, *p* = 0.050) and presence of personal allergic rhinitis (B = −9.269, *p* \< 0.0005) were negatively and independently associated with CDLQI.
  **SH**                               None of the studied blood markers were independently associated with SH.
  **TEWL**                             Serum concentration of IL-18 (B = 0.040, *p* = 0.010) was positively associated with TEWL.
  ------------------------------------ -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
